Payment overview · 2025
General Payments
$3,177.87
173 reported records · 26 companies
Healthcare provider profile · identity verified
Terry V Arnold, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LEXINGTON, NC · NPI 1326108887
Verified facts
What the public records show
CMS Open Payments records show Terry V Arnold, MD received $3,177.87 in general payments during 2025 across 173 reported records.
Novo Nordisk Inc accounted for 14.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Nuedexta, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Ubrelvy, Verquvo, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ubrelvy by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 208 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 408 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Rexulti by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 408 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $443.66 | 14.0% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $311.34 | 9.8% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $246.32 | 7.8% | 18 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $238.58 | 7.5% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $204.27 | 6.4% | 11 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $175.65 | 5.5% | 29 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $174.05 | 5.5% | 10 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $167.87 | 5.3% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $159.65 | 5.0% | 11 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $144.29 | 4.5% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $142.79 | 4.5% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $137.88 | 4.3% | 8 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $129.39 | 4.1% | 7 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $85.12 | 2.7% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $74.29 | 2.3% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $57.25 | 1.8% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $55.25 | 1.7% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $47.97 | 1.5% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $46.28 | 1.5% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $34.21 | 1.1% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.52 | 0.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.97 | 0.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.86 | 0.5% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $16.07 | 0.5% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $15.36 | 0.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.98 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,177.87 | 173 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $289.90 | 10 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $238.58 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $238.31 | 13 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $194.82 | 13 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $180.65 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $175.65 | 29 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $174.05 | 10 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $167.87 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $145.16 | 10 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $144.29 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $143.86 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $129.39 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $124.14 | 9 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $112.37 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $112.05 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $112.05 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $111.02 | 7 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $101.14 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $99.09 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $92.33 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $85.12 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $64.77 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $57.25 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $55.25 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $47.33 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $46.28 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $41.65 | 3 | 2025 |
Source payment records
|
|||||
| NUEDEXTA Normalized: nuedexta |
Drug | Otsuka America Pharmaceutical, Inc. | $40.25 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $34.21 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $27.29 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $12.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 408 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 208 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 220 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 123 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 104 | exact normalized | Medicare Part D |
| NUEDEXTA nuedexta |
2025 | Nuedexta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 215 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 170 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 69 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 182 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
123 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
135 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
208 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
220 | 36 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
408 | 71 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
182 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
220 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
104 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
170 | 25 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
215 | 38 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
69 | 14 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
170 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
408 | 71 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1046 | 225 |
| Atorvastatin Calcium | Atorvastatin Calcium | 830 | 191 |
| Amlodipine Besylate | Amlodipine Besylate | 770 | 169 |
| Furosemide | Furosemide | 762 | 188 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 747 | 122 |
| Gabapentin | Gabapentin | 716 | 138 |
| Pantoprazole Sodium | Pantoprazole Sodium | 705 | 160 |
| Omeprazole | Omeprazole | 696 | 157 |
| Alprazolam | Alprazolam | 645 | 104 |
| Lisinopril | Lisinopril | 605 | 141 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 571 | 151 |
| Lorazepam | Lorazepam | 524 | 111 |
| Losartan Potassium | Losartan Potassium | 502 | 110 |
| Sertraline Hcl | Sertraline Hcl | 437 | 83 |
| Metoprolol Tartrate | Metoprolol Tartrate | 421 | 90 |
| Tramadol Hcl | Tramadol Hcl | 420 | 98 |
| Eliquis | Apixaban | 408 | 71 |
| Metformin Hcl | Metformin Hcl | 404 | 108 |
| Potassium Chloride | Potassium Chloride | 397 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 392 | 87 |
| Trazodone Hcl | Trazodone Hcl | 382 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 368 | 99 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 338 | 93 |
| Hydrochlorothiazide | Hydrochlorothiazide | 333 | 87 |
| Clonazepam | Clonazepam | 315 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 296 | 65 |
| Allopurinol | Allopurinol | 294 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 279 | 69 |
| Mirtazapine | Mirtazapine | 278 | 47 |
| Donepezil Hcl | Donepezil Hcl | 276 | 51 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 268 | 38 |
| Carvedilol | Carvedilol | 265 | 65 |
| Meloxicam | Meloxicam | 246 | 65 |
| Simvastatin | Simvastatin | 240 | 53 |
| Famotidine | Famotidine | 234 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 232 | 58 |
| Jardiance | Empagliflozin | 220 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 218 | 49 |
| Ozempic | Semaglutide | 215 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 213 | 38 |
| Farxiga | Dapagliflozin Propanediol | 208 | 38 |
| Divalproex Sodium | Divalproex Sodium | 199 | 34 |
| Estradiol | Estradiol | 186 | 52 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 182 | 27 |
| Pregabalin | Pregabalin | 181 | 35 |
| Diazepam | Diazepam | 180 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 172 | 42 |
| Rexulti | Brexpiprazole | 170 | 25 |
| Memantine Hcl | Memantine Hcl | 165 | 39 |
| Baclofen | Baclofen | 157 | 32 |
| Finasteride | Finasteride | 156 | 43 |
| Xarelto | Rivaroxaban | 155 | 29 |
| Bupropion Xl | Bupropion Hcl | 154 | 35 |
| Montelukast Sodium | Montelukast Sodium | 152 | 38 |
| Oxycodone Hcl | Oxycodone Hcl | 148 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 147 | 33 |
| Ezetimibe | Ezetimibe | 145 | 36 |
| Azithromycin | Azithromycin | 142 | 125 |
| Buspirone Hcl | Buspirone Hcl | 142 | 25 |
| Myrbetriq | Mirabegron | 135 | 26 |
| Atenolol | Atenolol | 128 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 127 | 21 |
| Lactulose | Lactulose | 127 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 126 | 32 |
| Linzess | Linaclotide | 123 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 44 |
| Prednisone | Prednisone | 120 | 57 |
| Celecoxib | Celecoxib | 114 | 31 |
| Alendronate Sodium | Alendronate Sodium | 113 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 108 | 76 |
| Levetiracetam | Levetiracetam | 108 | 12 |
| Risperidone | Risperidone | 108 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 106 | 49 |
| Mounjaro | Tirzepatide | 104 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 102 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 102 | 15 |
| Valsartan | Valsartan | 101 | 31 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 100 | 26 |
| Zaleplon | Zaleplon | 99 | 32 |
| Amiodarone Hcl | Amiodarone Hcl | 94 | 14 |
| Spironolactone | Spironolactone | 94 | 25 |
| Fluconazole | Fluconazole | 90 | 45 |
| Glimepiride | Glimepiride | 90 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 89 | 20 |
| Ramipril | Ramipril | 88 | 24 |
| Mupirocin | Mupirocin | 87 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 21 |
| Temazepam | Temazepam | 80 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 21 |
| Januvia | Sitagliptin Phosphate | 78 | 11 |
| Propranolol Hcl | Propranolol Hcl | 77 | 14 |
| Naproxen | Naproxen | 76 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 76 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 17 |
| Aripiprazole | Aripiprazole | 74 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 72 | suppressed |
| Cephalexin | Cephalexin | 71 | 51 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 71 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 18 |
| Rybelsus | Semaglutide | 69 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 68 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 67 | 49 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 66 | 18 |
| Levofloxacin | Levofloxacin | 65 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 17 |
| Torsemide | Torsemide | 63 | 17 |
| Lovastatin | Lovastatin | 62 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 61 | 15 |
| Meclizine Hcl | Meclizine Hcl | 61 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 18 |
| Chlorthalidone | Chlorthalidone | 59 | 19 |
| Fentanyl | Fentanyl | 59 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 58 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 58 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 57 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | suppressed |
| Topiramate | Topiramate | 55 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 54 | 14 |
| Mometasone Furoate | Mometasone Furoate | 54 | 33 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 53 | 17 |
| Lamotrigine | Lamotrigine | 53 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 52 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 30 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 50 | 25 |
| Nyamyc | Nystatin | 49 | 30 |
| Ondansetron Odt | Ondansetron | 48 | 30 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | 11 |
| Ibuprofen | Ibuprofen | 47 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 26 |
| Spiriva Handihaler | Tiotropium Bromide | 46 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 45 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | 12 |
| Vilazodone Hcl | Vilazodone Hcl | 43 | suppressed |
| Glipizide | Glipizide | 42 | 11 |
| Midodrine Hcl | Midodrine Hcl | 42 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 42 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 41 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 41 | 13 |
| Latanoprost | Latanoprost | 41 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 41 | 11 |
| Xifaxan | Rifaximin | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 35 |
| Morphine Sulfate Er | Morphine Sulfate | 40 | suppressed |
| Nitroglycerin | Nitroglycerin | 40 | 26 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 26 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 39 | 13 |
| Sevelamer Carbonate | Sevelamer Carbonate | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 39 | 11 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 39 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 38 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | suppressed |
| Cefdinir | Cefdinir | 37 | 32 |
| Colestipol Hcl | Colestipol Hcl | 36 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Febuxostat | Febuxostat | 34 | suppressed |
| Methotrexate | Methotrexate Sodium | 34 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Movantik | Naloxegol Oxalate | 33 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 33 | 14 |
| Nystatin | Nystatin | 32 | 22 |
| Ketoconazole | Ketoconazole | 31 | 13 |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Letrozole | Letrozole | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 25 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Premarin | Estrogens, Conjugated | 22 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 21 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | 12 |
| Cefuroxime | Cefuroxime Axetil | 20 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Invokana | Canagliflozin | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | 12 |
| Metronidazole | Metronidazole | 20 | 15 |
| Naratriptan Hcl | Naratriptan Hcl | 20 | suppressed |
| Nystop | Nystatin | 20 | 13 |
| Verquvo | Vericiguat | 20 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Insulin Lispro | Insulin Lispro | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 18 | suppressed |
| Lumigan | Bimatoprost | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Silodosin | Silodosin | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 17 | 17 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 17 | suppressed |
| Perphenazine | Perphenazine | 17 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 15 |
| Prasugrel Hcl | Prasugrel Hcl | 16 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Trandolapril | Trandolapril | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,177.87 · 173 records | Novo Nordisk Inc | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, Belbuca, CAPLYTA, COMIRNATY, ELIQUIS, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FANAPT, FARXIGA, GEMTESA, HETLIOZ, IBSRELA, JARDIANCE, KISUNLA, LINZESS, Leqembi, MOUNJARO, NUEDEXTA, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, RELISTOR, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error